Stifel Bullish On Sotheby's Despite Legal RisksMark Melin
In light of activist hedge fund Third Point’s legal action in regards to questioning the legality of Sotheby's (NYSE:BID) poison pill measure, Stifel Nicolaus reiterated their Buy rating and $65 price target.
Legal opinion aside, fundamentals look good for Sotheby's
The research report does not take a legal . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.